Insider Buying: ProQR Therapeutics (NASDAQ:PRQR) CEO Acquires $238,500.00 in Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De purchased 150,000 shares of the stock in a transaction dated Tuesday, July 7th. The stock was purchased at an average cost of $1.59 per share, for a total transaction of $238,500.00. Following the completion of the purchase, the chief executive officer directly owned 150,000 shares of the company’s stock, valued at approximately $238,500. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

ProQR Therapeutics Price Performance

NASDAQ PRQR traded up $0.04 during mid-day trading on Wednesday, hitting $1.70. The stock had a trading volume of 1,118,532 shares, compared to its average volume of 681,486. The firm’s 50 day moving average is $1.61 and its 200 day moving average is $1.68. The stock has a market capitalization of $178.59 million, a price-to-earnings ratio of -3.49 and a beta of 0.04. ProQR Therapeutics N.V. has a twelve month low of $1.33 and a twelve month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, equities research analysts expect that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PRQR. JonesTrading dropped their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, June 26th. Weiss Ratings downgraded shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Chardan Capital decreased their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $7.33.

Institutional Trading of ProQR Therapeutics

Hedge funds have recently made changes to their positions in the business. Aberdeen Group plc increased its stake in ProQR Therapeutics by 28.4% during the 4th quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock worth $5,960,000 after buying an additional 651,853 shares during the period. Privium Fund Management B.V. grew its stake in shares of ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after acquiring an additional 359,475 shares in the last quarter. Invesco Ltd. purchased a new stake in shares of ProQR Therapeutics during the fourth quarter worth $51,000. Simplex Trading LLC increased its position in shares of ProQR Therapeutics by 44,169.0% during the fourth quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after acquiring an additional 44,169 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of ProQR Therapeutics by 73.9% in the fourth quarter. Geode Capital Management LLC now owns 84,909 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 36,087 shares in the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.